Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

VKTX Stock Valuation & Estimates The company is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 4.92, trailing 12-month book value, higher than 3 ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid the price fall. VKTX’s Progress With Its Obesity Program Encouraging The ...

Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price ... Viking Therapeutics, Inc. (VKTX). Viking Therapeutics currently ...

The downfall in stock price began after AstraZeneca reported ... candidate to clinical development for treating obesity. VKTX’s Non-Obesity Pipeline Shows Potential Apart from VK2735, Viking ...

(VKTX) closed at $42.53 in the latest trading ... these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank ...

VKTX’s shares are currently trading below the 50 and 200-day moving averages. Though this biotech’s progress with its obesity drug has been encouraging, the rising competition for developing obesity ...

This reduces the speculative value of Viking as a takeover target, which can also negatively impact its stock price. Overall, a stronger competitor and diminished acquisition prospects by a pharma ...